Low bone density and high sclerostin in non-functioning pituitary adenoma

dc.authorid0000-0002-5323-2257en_US
dc.authorid0000-0003-3326-5358en_US
dc.authorid0000-0002-1814-9773en_US
dc.contributor.authorPekkolay, Zafer
dc.contributor.authorYıldırım, Devran Varhan
dc.contributor.authorTuzcu, Şadiye Altun
dc.contributor.authorTaşdemir, Bekir
dc.contributor.authorTuzcu, Alpaslan Kemal
dc.date.accessioned2023-10-02T12:52:40Z
dc.date.available2023-10-02T12:52:40Z
dc.date.issued2023en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıklar Ana Bilim Dalıen_US
dc.description.abstractPurpose: Sclerostin reduces bone formation by inhibiting the Wnt signaling pathway in bone tissue. This study evaluated the serum sclerostin level in non-functioning pituitary adenoma (NFPA) patients and analyzed its relationship with bone metabolism. Method: The data of the patients who applied to the Dicle University Endocrinology, diagnosed with non-functioning pituitary adenoma, and the control group consisting of healthy individuals were included in the study. Serum sclerostin levels and DXA analysis parameters were evaluated and compared with healthy control groups. Results: The study consisted of 39 patients (F / M: 27/12) with NFPA (patient group) and 43 control groups (F / M: 26/17). There was no difference in terms of gender, age, height, weight and serum calcium, phosphorus, creatinine, 25-OH vitamin D, parathyroid hormone levels. Serum sclerostin levels (32.31 ± 1.53 ng / ml) in the patient group was found to be significantly higher than the control group (22.45 ± 8.9 ng / ml) (p < 0.001). BMD (Patients groups vs control group); total lumbar BMD (0.951-1.56 gr / cm2) (p < 0.001), femoral neck BMD (0.752-1.15 g / cm2) (p < 0.001), femoral total BMD (0.995- 1.63 gr / cm2) (p < 0.001), were found to be statistically significantly lower. Conclusion: This study provides the first evidence that serum sclerostin levels were increased in non-functioning pituitary adenomas, which showed that bone parameters were negatively affected.en_US
dc.identifier.citationPekkolay, Z., Yıldırım, D. V., Tuzcu, Ş. A., Taşdemir, B. ve Tuzcu, A. K. (2023). Low bone density and high sclerostin in non-functioning pituitary adenoma. Journal of Clinical Densitometry, 26(2), 1-5.en_US
dc.identifier.doi10.1016/j.jocd.2023.03.002en_US
dc.identifier.endpage5en_US
dc.identifier.issn1094-6950
dc.identifier.issue2en_US
dc.identifier.pmid37002004en_US
dc.identifier.scopus2-s2.0-85151457979en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1en_US
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S1094695023000124?via%3Dihub
dc.identifier.urihttps://hdl.handle.net/11468/12649
dc.identifier.volume26en_US
dc.identifier.wosWOS:001004039500001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorPekkolay, Zafer
dc.institutionauthorYıldırım, Devran Varhan
dc.institutionauthorTuzcu, Şadiye Altun
dc.institutionauthorTaşdemir, Bekir
dc.institutionauthorTuzcu, Alpaslan Kemal
dc.language.isoenen_US
dc.publisherElsevier Inc.en_US
dc.relation.ispartofJournal of Clinical Densitometryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBMDen_US
dc.subjectNon-functioning pituitary adenomaen_US
dc.subjectSclerostinen_US
dc.titleLow bone density and high sclerostin in non-functioning pituitary adenomaen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
Low Bone Density and High Sclerostin in Non-Functioning Pituitary Adenoma.pdf
Boyut:
108.67 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: